Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels

We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagno...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-10
Main Authors: Gu, Hong-Yue, Yin, Feng, Jiang, Li, Teng, Shi-Chao, Xue, Feng-Hua, Shi, Ming-Yu, Sun, Shao-Xia, Li, Xi-Dong, Su, Fang-Cheng, Zhu, Jing
Format: Article
Language:English
Subjects:
Adult
Atorvastatin Calcium - therapeutic use
Atrial fibrillation
Atrial Fibrillation - blood
Atrial Fibrillation - drug therapy
C-reactive protein
C-Reactive Protein - metabolism
Case-Control Studies
Cholesterol
Drug therapy
Female
Health aspects
Heart attacks
Humans
Male
Methods
Middle Aged
Odds Ratio
Patient outcomes
Publication Bias
Statins
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3
cites cdi_FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3
container_end_page 10
container_issue 2015
container_start_page 1
container_title BioMed research international
container_volume 2015
creator Gu, Hong-Yue
Yin, Feng
Jiang, Li
Teng, Shi-Chao
Xue, Feng-Hua
Shi, Ming-Yu
Sun, Shao-Xia
Li, Xi-Dong
Su, Fang-Cheng
Zhu, Jing
description We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47, P < 0.001 ). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69, P < 0.001 ) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71, P < 0.001 ), but not among Turkish population and using INA method (all P > 0.05 ). Egger’s test showed no publication bias ( P = 0.450 ). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.
doi_str_mv 10.1155/2015/402481
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4502280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A458161309</galeid><sourcerecordid>A458161309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3</originalsourceid><addsrcrecordid>eNqNks9rFDEUxwex2FJ78i4DXqQyNr8nuQjLYlthQWnrOWQnb3ZTZpKaZFb635vt1rX21FySx_vwTb4v36p6h9FnjDk_IwjzM4YIk_hVdUQoZo3ADL_enyk9rE5SukVlSSyQEm-qQyIIUYrLo2o1yyFuTMomO1_fRDB5BJ_rPsR6lqMzQ33ultENQwGCr6_ATh2k-hriNNaXbrVursEnl93G5ft63lyB6UoB9Y8YMhTNBWxgSG-rg94MCU4e9-Pq5_nXm_lls_h-8W0-WzQdJzI3THLJWU9byxFByoqOKE55ccp7C0wBSA6tUUj0S2kp6bCVRrS4VUpQiyw9rr7sdO-m5Qi2K16iGfRddKOJ9zoYp__veLfWq7DRrFxIJCoCHx8FYvg1Qcp6dKmD4t9DmJLGLcJSUSFehnKEBWUF_fAMvQ1T9GUSGgvFW8IpVf-olRlAO9-H8sRuK6pnjJffwxRtqU87qoshpQj93h1GehsKvQ2F3oWi0O-fDmTP_o1AAU53wNp5a367l6lBQaA3T2D-YOEPrBjGZw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695725339</pqid></control><display><type>article</type><title>Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Gu, Hong-Yue ; Yin, Feng ; Jiang, Li ; Teng, Shi-Chao ; Xue, Feng-Hua ; Shi, Ming-Yu ; Sun, Shao-Xia ; Li, Xi-Dong ; Su, Fang-Cheng ; Zhu, Jing</creator><contributor>Boukens, Bas J. D.</contributor><creatorcontrib>Gu, Hong-Yue ; Yin, Feng ; Jiang, Li ; Teng, Shi-Chao ; Xue, Feng-Hua ; Shi, Ming-Yu ; Sun, Shao-Xia ; Li, Xi-Dong ; Su, Fang-Cheng ; Zhu, Jing ; Boukens, Bas J. D.</creatorcontrib><description>We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47, P &lt; 0.001 ). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69, P &lt; 0.001 ) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71, P &lt; 0.001 ), but not among Turkish population and using INA method (all P &gt; 0.05 ). Egger’s test showed no publication bias ( P = 0.450 ). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2015/402481</identifier><identifier>PMID: 26229958</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Atorvastatin Calcium - therapeutic use ; Atrial fibrillation ; Atrial Fibrillation - blood ; Atrial Fibrillation - drug therapy ; C-reactive protein ; C-Reactive Protein - metabolism ; Case-Control Studies ; Cholesterol ; Drug therapy ; Female ; Health aspects ; Heart attacks ; Humans ; Male ; Methods ; Middle Aged ; Odds Ratio ; Patient outcomes ; Publication Bias ; Statins ; Studies</subject><ispartof>BioMed research international, 2015-01, Vol.2015 (2015), p.1-10</ispartof><rights>Copyright © 2015 Fang-Cheng Su et al.</rights><rights>COPYRIGHT 2015 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2015 Fang-Cheng Su et al. Fang-Cheng Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2015 Fang-Cheng Su et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3</citedby><cites>FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1695725339/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1695725339?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26229958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Boukens, Bas J. D.</contributor><creatorcontrib>Gu, Hong-Yue</creatorcontrib><creatorcontrib>Yin, Feng</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Teng, Shi-Chao</creatorcontrib><creatorcontrib>Xue, Feng-Hua</creatorcontrib><creatorcontrib>Shi, Ming-Yu</creatorcontrib><creatorcontrib>Sun, Shao-Xia</creatorcontrib><creatorcontrib>Li, Xi-Dong</creatorcontrib><creatorcontrib>Su, Fang-Cheng</creatorcontrib><creatorcontrib>Zhu, Jing</creatorcontrib><title>Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47, P &lt; 0.001 ). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69, P &lt; 0.001 ) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71, P &lt; 0.001 ), but not among Turkish population and using INA method (all P &gt; 0.05 ). Egger’s test showed no publication bias ( P = 0.450 ). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.</description><subject>Adult</subject><subject>Atorvastatin Calcium - therapeutic use</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - blood</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - metabolism</subject><subject>Case-Control Studies</subject><subject>Cholesterol</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health aspects</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Patient outcomes</subject><subject>Publication Bias</subject><subject>Statins</subject><subject>Studies</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNks9rFDEUxwex2FJ78i4DXqQyNr8nuQjLYlthQWnrOWQnb3ZTZpKaZFb635vt1rX21FySx_vwTb4v36p6h9FnjDk_IwjzM4YIk_hVdUQoZo3ADL_enyk9rE5SukVlSSyQEm-qQyIIUYrLo2o1yyFuTMomO1_fRDB5BJ_rPsR6lqMzQ33ultENQwGCr6_ATh2k-hriNNaXbrVursEnl93G5ft63lyB6UoB9Y8YMhTNBWxgSG-rg94MCU4e9-Pq5_nXm_lls_h-8W0-WzQdJzI3THLJWU9byxFByoqOKE55ccp7C0wBSA6tUUj0S2kp6bCVRrS4VUpQiyw9rr7sdO-m5Qi2K16iGfRddKOJ9zoYp__veLfWq7DRrFxIJCoCHx8FYvg1Qcp6dKmD4t9DmJLGLcJSUSFehnKEBWUF_fAMvQ1T9GUSGgvFW8IpVf-olRlAO9-H8sRuK6pnjJffwxRtqU87qoshpQj93h1GehsKvQ2F3oWi0O-fDmTP_o1AAU53wNp5a367l6lBQaA3T2D-YOEPrBjGZw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Gu, Hong-Yue</creator><creator>Yin, Feng</creator><creator>Jiang, Li</creator><creator>Teng, Shi-Chao</creator><creator>Xue, Feng-Hua</creator><creator>Shi, Ming-Yu</creator><creator>Sun, Shao-Xia</creator><creator>Li, Xi-Dong</creator><creator>Su, Fang-Cheng</creator><creator>Zhu, Jing</creator><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels</title><author>Gu, Hong-Yue ; Yin, Feng ; Jiang, Li ; Teng, Shi-Chao ; Xue, Feng-Hua ; Shi, Ming-Yu ; Sun, Shao-Xia ; Li, Xi-Dong ; Su, Fang-Cheng ; Zhu, Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Atorvastatin Calcium - therapeutic use</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - blood</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - metabolism</topic><topic>Case-Control Studies</topic><topic>Cholesterol</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health aspects</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Patient outcomes</topic><topic>Publication Bias</topic><topic>Statins</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Hong-Yue</creatorcontrib><creatorcontrib>Yin, Feng</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Teng, Shi-Chao</creatorcontrib><creatorcontrib>Xue, Feng-Hua</creatorcontrib><creatorcontrib>Shi, Ming-Yu</creatorcontrib><creatorcontrib>Sun, Shao-Xia</creatorcontrib><creatorcontrib>Li, Xi-Dong</creatorcontrib><creatorcontrib>Su, Fang-Cheng</creatorcontrib><creatorcontrib>Zhu, Jing</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Hong-Yue</au><au>Yin, Feng</au><au>Jiang, Li</au><au>Teng, Shi-Chao</au><au>Xue, Feng-Hua</au><au>Shi, Ming-Yu</au><au>Sun, Shao-Xia</au><au>Li, Xi-Dong</au><au>Su, Fang-Cheng</au><au>Zhu, Jing</au><au>Boukens, Bas J. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>2015</volume><issue>2015</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47, P &lt; 0.001 ). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69, P &lt; 0.001 ) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71, P &lt; 0.001 ), but not among Turkish population and using INA method (all P &gt; 0.05 ). Egger’s test showed no publication bias ( P = 0.450 ). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>26229958</pmid><doi>10.1155/2015/402481</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2015-01, Vol.2015 (2015), p.1-10
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4502280
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Adult
Atorvastatin Calcium - therapeutic use
Atrial fibrillation
Atrial Fibrillation - blood
Atrial Fibrillation - drug therapy
C-reactive protein
C-Reactive Protein - metabolism
Case-Control Studies
Cholesterol
Drug therapy
Female
Health aspects
Heart attacks
Humans
Male
Methods
Middle Aged
Odds Ratio
Patient outcomes
Publication Bias
Statins
Studies
title Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A46%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atorvastatin%20Treatment%20for%20Atrial%20Fibrillation%20Reduces%20Serum%20High-Sensitivity%20C-Reactive%20Protein%20Levels&rft.jtitle=BioMed%20research%20international&rft.au=Gu,%20Hong-Yue&rft.date=2015-01-01&rft.volume=2015&rft.issue=2015&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2015/402481&rft_dat=%3Cgale_pubme%3EA458161309%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c528t-485854f37d50209d6c295351555fde49ee85e7a906fb8d32c1d8a67179963d0d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1695725339&rft_id=info:pmid/26229958&rft_galeid=A458161309&rfr_iscdi=true